Prometrium Cost in District of Columbia (2026): Prices, Insurance, and Savings

What Prometrium Actually Costs in D.C. Right Now

The gap between the sticker price and what patients pay in Washington, D.C. Is wide. AbbVie's manufacturer list price for brand-name Prometrium (micronized progesterone, 200 mg oral capsules) stands at $180 per month. That number rarely reflects what anyone hands over at the counter. The average cash-pay price across District of Columbia retail pharmacies in 2026 is approximately $45 per month for a 30-day supply.

Brand vs. Generic Pricing

Generic micronized progesterone capsules account for the bulk of prescriptions filled in D.C. Since the patent on Prometrium expired, multiple manufacturers produce the generic, and competition has pulled prices well below the original brand. Patients paying cash without insurance should expect to pay $40 to $55 at most chain pharmacies, with independent pharmacies occasionally pricing slightly higher due to lower purchasing volume.

Why Prices Vary by Pharmacy

Pharmacy benefit managers negotiate different acquisition costs with wholesalers. A CVS location on Connecticut Avenue may charge $42 for the same 30-day supply that costs $51 at an independent pharmacy in Southeast D.C. Calling two or three pharmacies before filling a prescription can save $10 to $15 per month. Discount platforms like GoodRx and RxSaver aggregate these prices, though the posted amounts are not always current.

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial established micronized progesterone as a preferred agent for endometrial protection during estrogen therapy, demonstrating favorable lipid effects compared to medroxyprogesterone acetate [1]. That clinical foundation is one reason Prometrium remains widely prescribed and broadly covered by insurers in D.C.

D.C. Medicaid Coverage for Prometrium

District of Columbia Medicaid covers Prometrium, but a prior authorization (PA) requirement applies. This means a prescriber must submit documentation showing the medication is medically necessary before the plan will pay.

How to Get Prior Authorization Approved

The PA process in D.C. Typically requires a diagnosis of secondary amenorrhea or a documented need for endometrial protection in a patient receiving estrogen therapy. Prescribers submit the request through the D.C. Medicaid pharmacy benefit manager. Approval timelines range from 24 to 72 hours for standard requests. Urgent requests can be processed within 24 hours.

What If the PA Is Denied

If the initial PA is denied, the prescriber can file an appeal. D.C. Medicaid allows one level of appeal before an external review. During the appeal period, patients may need to pay out of pocket or use a discount card. Some prescribers switch to generic micronized progesterone on initial submission, which may face fewer PA hurdles depending on the formulary tier.

For patients enrolled in D.C. Medicaid managed care plans (such as AmeriHealth Caritas or CareFirst Community Health Plan of D.C.), formulary placement and PA criteria can differ from fee-for-service Medicaid. Checking with the specific managed care plan's pharmacy line before filling saves time.

Compounded Micronized Progesterone in D.C.

Compounded micronized progesterone is available in the District of Columbia through licensed 503A compounding pharmacies. These pharmacies operate under FDA regulation and D.C. Board of Pharmacy oversight, preparing patient-specific prescriptions.

Cost and Access

Compounded micronized progesterone typically costs around $25 per month in D.C., a significant discount compared to both the brand and generic retail options. The trade-off: compounded products do not carry FDA approval for a specific indication, and they are not subject to the same bioequivalence testing as FDA-approved generics.

Legal Status and Quality Considerations

503A compounding is legal in all 50 states and D.C. The pharmacist must hold a valid D.C. License, and the prescription must be patient-specific (not dispensed in bulk without individual prescriptions). The FDA's 2023 guidance on compounding under Section 503A remains the governing framework [2].

Patients considering compounded progesterone should verify the pharmacy's accreditation. The Pharmacy Compounding Accreditation Board (PCAB) and state board inspection records provide transparency into quality practices. The American College of Obstetricians and Gynecologists (ACOG) has noted that FDA-approved progesterone products should be used when available, given more rigorous manufacturing standards [3].

When Compounding Makes Clinical Sense

Some patients require doses or delivery forms not commercially available. A patient who needs 50 mg or 300 mg capsules, for example, may benefit from compounding, since commercial Prometrium comes only in 100 mg and 200 mg capsules. Patients with peanut oil allergies (Prometrium's capsule vehicle contains peanut oil) represent another population where compounding fills a gap.

Insurance Coverage Beyond Medicaid

Most commercial insurance plans operating in the District of Columbia cover generic micronized progesterone. Brand Prometrium coverage varies.

Major Carriers in D.C.

CareFirst BlueCross BlueShield, the dominant commercial carrier in the D.C. Metro area, generally lists generic micronized progesterone on Tier 1 or Tier 2. Aetna, Cigna, and UnitedHealthcare plans sold through the DC Health Benefit Exchange (DC Health Link) also cover the generic. Brand Prometrium, when covered, usually sits on Tier 3, carrying a higher copay.

Employer-Sponsored Plans

Large federal employers represent a significant share of D.C.'s insured population. The Federal Employees Health Benefits (FEHB) Program covers micronized progesterone under most plan options, including Blue Cross Blue Shield FEP, GEHA, and Kaiser Permanente Mid-Atlantic. Copays under FEHB plans range from $5 to $30 for generic and $30 to $60 for brand.

Medicare Part D

Medicare Part D plans in D.C. Cover generic micronized progesterone. The 2026 Inflation Reduction Act provisions cap out-of-pocket prescription costs at $2,000 per year for Part D enrollees, which affects patients taking multiple medications [4]. For a patient whose only prescription is micronized progesterone, the monthly cost under Part D is typically $5 to $15.

The AbbVie Savings Card

AbbVie (which acquired the Prometrium brand through its purchase of Allergan, the successor to Solvay) offers a manufacturer copay card for commercially insured patients.

How It Works

The savings card reduces out-of-pocket cost for brand Prometrium. Eligible patients pay as little as $30 per month, with AbbVie covering the difference up to a specified annual maximum. The card does not apply to government-funded insurance (Medicaid, Medicare, Tricare, VA).

Eligibility Restrictions

Patients must have commercial insurance that covers Prometrium. Cash-pay patients and those on government plans are excluded. The card is activated online or through the prescriber's office. It resets annually.

For patients whose insurance does not cover brand Prometrium at all, the savings card will not help. In those cases, generic micronized progesterone or compounded options provide the most cost-effective path.

Telehealth Prescribing in D.C.

The District of Columbia permits telehealth prescribing of Prometrium and generic micronized progesterone. D.C. Enacted permanent telehealth parity legislation, meaning insurers must cover telehealth visits the same way they cover in-person visits.

Practical Implications

A patient can receive a new prescription or refill for micronized progesterone through a video or audio visit with a licensed prescriber. The prescription is sent electronically to any D.C. Pharmacy. Several telehealth platforms operating in D.C. Prescribe hormone therapy, including progesterone, after a clinical evaluation.

Prescriber Requirements

The prescribing clinician must hold a D.C. Medical license or practice under a valid interstate compact. Nurse practitioners in D.C. Have full practice authority, meaning they can prescribe micronized progesterone independently without physician oversight. This expands access, particularly for patients using telehealth-first platforms.

The Endocrine Society's 2022 clinical practice guideline on menopausal hormone therapy supports progesterone use for endometrial protection in women with a uterus taking systemic estrogen [5]. Telehealth does not change the clinical indication or monitoring requirements.

How to Find the Lowest Price

Several strategies can reduce the cost of micronized progesterone in D.C. Below the average $45 cash-pay price.

Step 1: Check Insurance Formulary Placement

Before filling, call the number on the back of the insurance card and ask which tier micronized progesterone occupies. Tier 1 generics carry copays of $5 to $15 at most plans. If the plan requires a PA, ask the prescriber to submit it before the pharmacy visit.

Step 2: Compare Cash Prices

Even insured patients sometimes pay less with a discount card than with their copay. This is especially true for high-deductible health plans. Compare the insurance copay against cash-pay options at two or three pharmacies.

Step 3: Consider Compounded Progesterone

If the prescriber agrees that compounded progesterone is appropriate, a 503A pharmacy can fill the prescription for roughly $25 per month. Verify the pharmacy's licensure through the D.C. Board of Pharmacy's online database.

Step 4: Use Manufacturer or Nonprofit Assistance

The AbbVie savings card covers brand Prometrium for commercially insured patients. For uninsured patients, NeedyMeds and RxAssist maintain databases of patient assistance programs. Some D.C.-based community health centers offer sliding-scale pharmacy services.

Clinical Context: Why Progesterone Matters in HRT

Micronized progesterone is not optional for most women on estrogen therapy. It is prescribed to prevent endometrial hyperplasia, a thickening of the uterine lining that can progress to endometrial cancer. The PEPI trial demonstrated that micronized progesterone protected the endometrium while producing fewer adverse effects on HDL cholesterol compared to medroxyprogesterone acetate (MPA) [1].

Dosing and Administration

The standard dose for endometrial protection is 200 mg orally at bedtime for 12 to 14 days per month (cyclic regimen) or 100 mg nightly (continuous regimen). Bedtime dosing reduces the sedative side effects that some patients experience. The capsule should be taken on an empty stomach or with a small amount of food, as high-fat meals can increase peak serum levels.

Monitoring

Patients on micronized progesterone for HRT should undergo periodic clinical assessment, including evaluation of bleeding patterns. The North American Menopause Society (NAMS) recommends annual reassessment of HRT, including the progesterone component [6]. No routine blood level monitoring is required for oral micronized progesterone when used at standard doses.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the Women's Health Initiative hormone therapy trials, has stated: "Micronized progesterone appears to have a more favorable risk profile than synthetic progestins, particularly regarding breast cancer risk and cardiovascular markers" [7].

The WHI observational data and the French E3N cohort study (N=80,377) found that estrogen combined with micronized progesterone was not associated with increased breast cancer risk over a mean follow-up of 8.1 years, while estrogen plus synthetic progestins showed a statistically significant increase [8].

D.C.-Specific Regulatory Notes

The District of Columbia's pharmaceutical field has several features that affect progesterone access and cost.

Pharmacy Benefit Transparency

D.C. Enacted pharmacy benefit manager transparency requirements, which mandate disclosure of drug pricing spreads and rebate pass-through rates. This regulatory environment may contribute to more competitive generic pricing compared to states without such mandates.

Parity Laws

D.C.'s insurance parity laws require that hormone therapy prescribed for menopausal symptoms receive the same coverage as medications for other chronic conditions. Insurers cannot impose higher cost-sharing on HRT relative to comparable drug classes without actuarial justification.

The average out-of-pocket cost for a D.C. Resident filling generic micronized progesterone with commercial insurance is $10 to $20 per month. For Medicaid enrollees with an approved PA, the cost is $0 to $3 per fill.